Explore the words cloud of the MCDS-Therapy project. It provides you a very rough idea of what is the project "MCDS-Therapy" about.
The following table provides information about the project.
UNIVERSITY OF NEWCASTLE UPON TYNE
|Coordinator Country||United Kingdom [UK]|
|Total cost||5˙697˙390 €|
|EC max contribution||5˙697˙390 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2017-12-01 to 2022-11-30|
Take a look of project's partnership.
|1||UNIVERSITY OF NEWCASTLE UPON TYNE||UK (NEWCASTLE UPON TYNE)||coordinator||2˙175˙161.00|
|2||ISTITUTO ORTOPEDICO RIZZOLI||IT (BOLOGNA)||participant||782˙175.00|
|3||UNIVERSITAETSKLINIKUM FREIBURG||DE (FREIBURG)||participant||657˙569.00|
|4||SCIOMICS GMBH||DE (HEIDELBERG)||participant||604˙030.00|
|6||MURDOCH CHILDRENS RESEARCH INSTITUTE||AU (PARKVILLE)||participant||318˙625.00|
|7||FINDACURE FOUNDATION||UK (CAMBRIDGE)||participant||309˙235.00|
|8||ASSISTANCE PUBLIQUE HOPITAUX DE PARIS||FR (PARIS)||participant||211˙479.00|
|9||GUYS AND ST THOMAS' NHS FOUNDATIONTRUST||UK (London)||participant||197˙428.00|
|10||UNIVERSITAIR ZIEKENHUIS ANTWERPEN||BE (EDEGEM)||participant||120˙750.00|
Genetic skeletal diseases (GSDs) are an extremely diverse and complex group of rare genetic diseases that affect the development the skeleton. There are more than 450 unique and well-characterised phenotypes that range in severity from relatively mild to severe and lethal forms. Although individually rare, as a group of related genetic skeletal diseases, GSDs have an overall prevalence of at least 1 per 4,000 children, which extrapolates to a minimum of 225,000 people in the 27 member states and candidate countries of the EU. This burden in pain and disability leads to poor quality of life and high healthcare costs. Metaphyseal chondrodysplasia, type Schmid (MCDS) results from mutations in collagen X and affects <1/100,000 of the population. Mutant collagen X molecules miss-fold during synthesis and are retained within the endoplasmic reticulum (ER) of hypertrophic chondrocytes, thereby causing ER stress. Our extensive pre-clinical studies have shown that carbamazepine (CBZ) can alleviate ER stress caused by the expression of mutant collagen X and restore bone growth in a validated mouse model of MCDS. CBZ is an FDA approved drug used for the treatment of epilepsy and bipolar disorder and received orphan drug designation by the European Commission for the treatment of MCDS in September 2016. MCDS-Therapy is a 5-year collaborative project comprising world-renown clinical centres and SMEs to advance the repurposing of CBZ for MCDS (up to the Marketing Authorization Application dossier) through a multicentre and multinational (EU & AUS) clinical trial (Phase1, Phase2/3). MCDS-Therapy also encompasses biomarker development and health economics assessment studies to deliver by 2022 an innovative and affordable (CBZ already exists in a generic form) repurposed therapy for MCDS along with the diagnosis/prognosis tools to personalise the treatment strategy.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MCDS-THERAPY" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MCDS-THERAPY" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
Global Alliance for Chronic Diseases SecretariatRead More
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired PneumoniaRead More